Literature DB >> 21917886

Optimizing initial therapy for HIV infection.

Mark W Hull, Julio S G Montaner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21917886      PMCID： PMC3173504          DOI： 10.1093/infdis/jir506

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  21 in total

1.  Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

Authors:  Frank A Post; Graeme J Moyle; Hans Jürgen Stellbrink; Pere Domingo; Daniel Podzamczer; Martin Fisher; Anthony G Norden; Matthias Cavassini; Armin Rieger; Marie-Aude Khuong-Josses; Teresa Branco; Helen C Pearce; Naomi Givens; Cindy Vavro; Michael L Lim
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

2.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Judith Feinberg; Karen Tashima; Robert L Murphy; Margaret A Fischl
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

3.  Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

Authors:  Rebekah L Puls; Preeyaporn Srasuebkul; Kathy Petoumenos; Christoph Boesecke; Chris Duncombe; Waldo H Belloso; Jean-Michel Molina; Lin Li; Anchalee Avihingsanon; Brian Gazzard; David A Cooper; Sean Emery
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

4.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

5.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Authors:  Joel E Gallant; Edwin DeJesus; José R Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

6.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Authors:  Eric S Daar; Camlin Tierney; Margaret A Fischl; Paul E Sax; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Keith A Pappa; William C Woodward; Kristine Patterson; Hector Bolivar; Constance A Benson; Ann C Collier
Journal:  Ann Intern Med       Date:  2011-02-14       Impact factor: 25.391

7.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

8.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

Authors:  Edwin DeJesus; Gisela Herrera; Eugenio Teofilo; Jan Gerstoft; Carlos Beltran Buendia; J David Brand; Cynthia H Brothers; Jaime Hernandez; Steve A Castillo; Tab Bonny; E Randall Lanier; Trevor R Scott
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

9.  Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

Authors:  Miguel Goicoechea; Shanshan Liu; Brookie Best; Shelly Sun; Sonia Jain; Carol Kemper; Mallory Witt; Catherine Diamond; Richard Haubrich; Stan Louie
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

10.  Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

Authors:  Jose R Arribas; Anton L Pozniak; Joel E Gallant; Edwin Dejesus; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Charles B Holmes; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.